DMF treatment inhibits metastasis of CTCL tumors in vivo. Livers were collected from orthotopically HH xenografted tumor bearers that were treated once daily IP with either 30 mg/kg bodyweight DMF or PBS as control (n = 37, each). (A) Representative macroscopic pictures of an explanted liver of the respective mouse from either a PBS-treated (upper) or a DMF-treated (lower) animal in the intradermal model. (B) Representative pictures of hematoxylin and eosin–stained liver specimens (upper panels, 20×; lower panels, 200×). (C) Semiquantitative score of HH T-cell infiltrate areas within the mouse livers (0% to 25% liver area covered by T cells = 0; 25% to 50% liver area covered by T cells = 1; 50% to 75% liver area covered by T cells = 2; 75% to 100% liver area covered by T cells = 3). (D) Median of the semiquantitative score of HH-T cell infiltrates in liver of DMF- and PBS-treated HH xenograft tumor bearers. (E) Representative picture of liver specimens derived from DMF- and PBS-treated HH xenograft tumor bearers immunohistochemically stained for cleaved caspase 3. Note the positive staining in T-cell foci of DMF-treated tumor bearers, but not in surrounding host tissue. *P < .05.